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Human prion diseases like Creutzfeldt-Jakob disease
are infectious, inherited, or sporadic neurodegenera-
tive disorders , characterized by the accumulation
of an abnormal isoform of the host-encoded prion
protein. This affects nervous tissue in sporadic
Creutzfeldt-Jakob disease and, additionally , in lym-
phoid tissue in bovine spongiform encephalopathy-
linked variant Creutzfeldt-Jakob disease. Experi-
mental studies have established the involvement of
cells of the lymphoid and peripheral nervous sys-
tem in the transport of prions to their target central
nervous system tissue. To evaluate the role of vessel
wall-associated mobile cells , we obtained formalin-
fixed tissue blocks from various brain regions
and/or basal arteries from sporadic , variant and
iatrogenic Creutzfeldt-Jakob disease , and un-
selected control cases. We demonstrate disease-
associated prion protein deposits in intracranial
vessel walls , in sporadic and variant Creutzfeldt-
Jakob disease by performing immunohistochemical
staining and paraffin-embedded tissue blotting. Us-
ing double immunofluorescence, these deposits co-
localize with HLA-DR and S-100 immunoreactive
cells in the intima, which are components of the
vascular-associated dendritic cell network, as well
as with HLA-DR and CD-68 immunopositive macro-
phages of the intima and media. We conclude that
mobile cells in vessel walls like dendritic and
monocyte/macrophage lineage cells may be in-
volved in spread of disease-associated prion protein
and possibly also of infectivity. (Am J Pathol 2002,
161:1979–1984)
Prion diseases (PrD) are infectious, inherited, or sporadic
neurodegenerative disorders. Beside the classical neuro-
pathological triad (spongiform change, astrogliosis, and
neuronal loss), PrD are characterized by the accumulation
of an abnormal isoform of the host-encoded prion protein
(PrP).1 In human PrD, this affects nervous tissue in sporadic
Creutzfeldt-Jakob disease (sCJD)2 as well as in lymphoid
tissue in bovine spongiform encephalopathy-linked variant
Creutzfeldt-Jakob disease (vCJD).3,4
Tissue-related diagnosis of PrD can be achieved by
post-mortem examination of the brain2 and also by de-
tection of disease-associated prion protein (PrPSc) in lym-
phoid tissue biopsy in vCJD.4 Detection of PrPSc in blood
samples as a specific diagnosis for PrD would require its
transport across vessel walls. As PrPSc is postulated as
the infectious particle in PrD,1 this transport can also be
interpreted as spread of infectivity. Blood transfusion is
not considered to carry a risk in sporadic cases,5 al-
though it may transmit disease in acquired PrD.6 To
evaluate this pathway we examined intracranial and ex-
tracranial vessels in different PrD subtypes, and we dem-
onstrate the presence of PrPSc in vessel walls.
Materials and Methods
Case Selection
Formalin-fixed, paraffin-embedded tissue blocks from the
cerebral cortex, basal ganglia, thalamus, brain stem, cere-
bellum and/or basal arteries (eg, basilar artery and/or
branches of circulus Willisi) were obtained from 30 sCJD, 17
vCJD, 4 iatrogenic (growth hormone application) CJD
(iCJD), and 30 unselected control cases with a variety of
neuropathological diagnoses including brain tumors, in-
flammatory, neurodegenerative, and cerebrovascular dis-
eases. In three sCJD, two vCJD, and two controls we inves-
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tigated extracranial segments of carotid artery and/or
ascending aorta as well.
Immunocytochemistry
For detection of PrPSc, we stained sections with 3F4 (mono-
clonal, 1:500, Senetek PLC, Napa, CA, USA) after a three-
tiered tissue pretreatment, including 10 minutes of hydrated
autoclaving at 121°C, 5 minutes of 96% formic acid, and 2
hours of 4 mol/L guanidine thiocyanate at 4°C. In cases with
immunoreactivity (IR) in the vessel wall, we then obtained
adjacent sections and used antibodies 6H4 (monoclonal,
1:500, Prionics, Zurich, Switzerland) and 12F10 (monoclo-
nal, 1:1000, CEA, Fontenay-aux-Roses, France). To charac-
terize labeled cells, we performed immunostaining for
HLA-DR (CR3/43, monoclonal, 1:100, DAKO, Glostrup,
Denmark), CD 68 (KP1, monoclonal, 1:100, DAKO), and
S100 (polyclonal, 1:2000, DAKO). As a secondary system,
we used the ChemMate detection kit (DAKO). Negative
controls included omission or substitution of primary anti-
bodies by nonspecific, isotype-matched antibodies.
Double Immunofluorescence
Double immunofluorescent labeling was evaluated by a
Zeiss LSM 510 confocal laser microscope. The fluores-
cent-labeled secondary antibody for anti-PrP antibodies
was Alexa Fluor 488 goat anti-mouse IgG (1:200 Molec-
ular Probes, Eugene, OR, USA), for HLA-DR and CD68
we used Alexa Fluor 633 goat anti-mouse IgG (1:200,
Molecular Probes), and for S-100 Alexa Fluor 633 goat
anti-rabbit IgG (1:200, Molecular Probes) was utilized.
We used argon 488-nm and helium/neon 633-nm lasers
to elicit immunofluorescent staining. For nucleic acid
counterstain we used SYTOX orange nucleic acid stain
(1:1000, Molecular Probes) and a helium/neon 543-nm
laser.
Paraffin-Embedded Tissue Blot
Paraffin-embedded tissue (PET) blot was performed on
basal intracranial arteries from one sCJD and extracranial
carotid and aorta from one vCJD case. Paraffin-embed-
ded tissue sections were placed onto nitro-cellulose
Figure 1. Disease-associated prion protein (PrP) deposits in vessel walls. a: PrP immunoreactivity (IR) (indicated by an arrow) in the media of basilar artery
in sporadic Creutzfeldt-Jakob disease (sCJD) (3F4; magnification, 100; enlarged in right upper corner, magnification, 750). b: Perivascular PrP IR (left side
of picture; 12F10; magnification,750) correlates with CD68 IR (right side of picture; magnification,750) in variant CJD (vCJD). c: Extensive PrP IR throughout
an intracerebral (basal ganglia) vessel wall in vCJD (3F4; magnification, 500). d: PrP IR in the outer part of the media in extracranial carotid artery in vCJD (6H4;
magnification 200; enlarged in right upper corner, magnification, 750). e: PrP IR (left side of picture; 3F4; magnification, 200) in a deep perforating artery
in sCJD correlates with CD68 IR (right side of picture; magnification, 200). f: PrP IR (left side of picture; 3F4; magnification, 200) in a deep perforating artery
in sCJD correlates with HLA-DR IR (right side of picture; magnification, 200).
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membrane for detection of PrPSc using the antibody 3F4
(monoclonal, 1:500, DAKO, Denmark) after proteinase K
digestion. Labeling was carried out following the protocol
of Schulz-Schaeffer et al,7 with the alkaline phosphatase-
coupled rabbit anti-mouse antibody replaced by an avi-
din-biotin system. A negative control, in which the pri-
mary antibody was omitted, was included for each
section examined. Labeling was observed using a ste-
reoscopic microscope.
Results
Using specific pretreatment and an immunostaining pro-
cedure for PrPSc,8 we observe focal granular PrP IR in
intracranial vessel walls of 6 of 30 sCJD, 3 of 17 vCJD,
and none of the iCJD and control cases. It locates pre-
dominantly to the media of deep perforating and occa-
sionally of meningeal and basal arteries (Figure 1a) as
well as of small parenchymal vessels. Rarely do we ob-
serve it in the intima. We do not observe a correlation
between PrP deposits in the brain parenchyma (eg, dif-
fuse/synaptic, plaque) and presence of vessel wall PrP
IR. In cases where we find PrP deposits in the vessel wall,
it can be seen most often in more than one vessel and in
different brain regions, whereas in other cases (iCJD),
serial sections covering about 100 m did not reveal PrP
vessel wall deposits. In addition, perivascular PrP depos-
its are not only predominant in vCJD (Figure 1b) and
iCJD, but also in sCJD cases. Nevertheless, as we rarely
found more extensive PrP aggregates throughout the
vessel wall (Figure 1c), we excluded their amyloid nature
by the absence of congophilia and birefringence.
In extracranial carotid (Figure 1d) and ascending aorta
we observe fine granular PrP IR in 2 of 2 vCJD, 0 of 3 of
sCJD cases, and 0 of 2 controls. This is rather wide-
spread and predominates in the outer part of the media
and less in the intima and inner part of the media.
Using the PET blot, small, intense areas of PrP positiv-
ity are also observed within the intracranial vessels in one
case of sCJD, selected from the six immunocytochemi-
cally positive sCJD cases. In many of the vessels, these
intense clustered deposits appear to follow a linear pat-
tern of labeling (Figure 2). Extracranial carotid and aorta
vessels in one vCJD case, selected from the two immu-
nocytochemically positive vCJD cases, were found to be
negative for PrP using the PET blot.
In adjacent sections of intracranial vessels and in dou-
ble-immunofluorescent labeling, PrP deposits, in part,
co-localize in the perivascular area and in the media of
vessels with CD68 IR (Figure 1b) and HLA-DR IR (Figure
1f and Figure 3,a–d) cells, and in the intima with HLA-DR
IR and CD68 IR (Figure 1e and Figure 3, e–h) or S-100 IR
cells (Figure 3, i–l).
Discussion
Here we demonstrate the presence of PrP IR in vessel
walls. We think that this represents predominantly PrPSc.
We did not see similar IR in control cases, moreover,
isotype antibody controls were negative. All three applied
monoclonal anti-PrP antibodies, including 6H4 and
12F10 that we recently showed to be most reliable for
PrPSc detection,8 immunostained these deposits. Further-
more, PET blot studies fully support the immunocyto-
chemical findings in the intracranial vessels, and confirm
that protease-resistant PrP is present within the wall of the
vessels in a focal distribution, consistent with the local-
ization also demonstrated by double-immunofluores-
cence labeling. This type of PrP IR in vessel walls must be
differentiated from that seen in stop mutation at codon
Figure 2. Small, intense foci of disease-associated PrP positivity within the intracranial vessels in sporadic Creutzfeldt-Jakob disease visualized by the PET blot
technique (a). These intense clustered deposits appear to follow a linear pattern of labeling (b). The control section for these in which the antibody was omitted
is shown in (c). Magnification, 60.
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145 of the PRNP9 since the presently described form
lacks amyloid features.
The PET blot studies on two extracranial vessels of one
vCJD case were unable to demonstrate protease-resis-
tant PrP. The immunocytochemical findings in these ves-
sels are therefore of uncertain significance at present.
Possible explanations include up-regulation of the normal
cellular isoform of the protein, or a conformational transi-
tion of PrP which is protease-sensitive but disease-asso-
ciated, as has been recently described using conforma-
tion-dependent immunoassay in hamsters inoculated
with different scrapie strains.10 However, the most likely
explanation might be that the very fine granular PrP de-
posits seen by immunocytochemistry are not visible in a
“gross” method such as a PET blot. Further studies (in-
cluding Western blot analysis and experimental transmis-
sion) are required to investigate these intriguing possibil-
ities.
We did not detect any vessel wall PrP IR in the four
iCJD cases. On one hand we examined only few cases,
but, on the other hand, we performed serial sectioning
covering about 100 m without any result. In any case,
we cannot exclude the possibility of missing focal PrP
deposits in these vessels. The reason for not detecting
PrP-IR in iCJD, if confirmed, remains obscure at present.
Intracranial vessel wall PrP deposits may represent PrPSc
derived from the periarterial interstitial fluid, which joins
the cerebrospinal fluid that may harbor PrPSc11,12 in
some, but not all, CJD cases.13 Our results resemble the
findings in Alzheimer’s disease, where -amyloid depos-
its are seen in intracranial but not in extracranial arteries.
It is suggested that -amyloid, often located perivascu-
larly, follows interstitial fluid drainage along the periarte-
rial space of intracerebral, leptomeningeal arteries, and
intracranial carotid to join deep cervical lymph nodes.14
The MHC class II antigen HLA-DR is expressed on
numerous immunocompetent cells in the vasculature, in-
cluding dendritic cells and macrophages.15 We identified
one PrPSc-associated cell type in the vessel wall and
perivascular area as CD68-positive macrophages, which
Figure 3. Disease-associated prion protein (PrP) co-localizes with immunocompetent cells in vessel walls. a–d: PrP co-localization (indicated by an arrow) with
HLA-DR in the media of a leptomeningeal artery in sporadic Creutzfeldt-Jakob disease (sCJD) (3F4/HLA-DR double immunofluorescence; magnification, 600;
green color represents PrP, red HLA-DR represents immunopositivity, blue color indicates the nuclei; Int, intima; Med, media of vessel wall). All colors are
combined in d. In the lumen of the artery red blood cells and between intima and media, the internal elastic layer shows autofluorescence. e–h: PrP co-localization
(indicated by an arrow) with CD68 in the intima of a basal artery in sCJD (3F4/CD68 double immunofluorescence; magnification, 1000; green color represents
PrP, red CD68 indicates immunopositivity, blue color indicates the nuclei; Int, intima; Med, media of vessel wall). All colors are combined in h. i–l: PrP
co-localization with S-100 in the intima of a basal artery in sCJD (3F4/CD68 double immunofluorescence; magnification, 600; green color represents PrP, red
S-100 represents immunopositivity, blue color indicates the nuclei; Int, intima; Med, media of vessel wall). All colors are combined in l. Between intima and media,
the internal elastic layer (i and l) shows autofluorescence.
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have a scavenger role in the central nervous system.16,17
Macrophages are important in scrapie pathogenesis.
They may take up PrPSc, sequester scrapie infectivity,
and impair early scrapie agent replication,18–20 or might
be vehicles for exporting PrPSc from the brain to the
periphery.
In a recent study, occasional perivascular macro-
phages surrounding cortical capillaries were PrP-immu-
noreactive in some non-PrD cases,21 proposing that they
express PrPC. The abundant aggregated PrP deposits in
the perivascular area (Figure 1b), some of which were
related to CD68 IR cells, can be distinguished from these,
as they represent disease-associated PrP deposits that
are absent in non-PrD cases. Perivascular macrophages
of the brain have a high rate of turnover by bone marrow-
derived blood cells22,23 and might represent a pathway
for neuroinvasion of vCJD that is alternatively spread
along peripheral nerves.24
In addition to neural tissue, S-100 is expressed in
vascular-associated dendritic cells (VADC).25 Dendritic
cells are potentially mobile, antigen processing, and pre-
senting cells with endophagocytic and lysosomal activ-
ity,26 and thus are ideal candidates for transport of the
infectious agent. VADCs, a network of which is known to
be present in arterial vessels of healthy individuals25 are
also related to atherosclerotic lesions with a possible role
of T-cell activation.27 Dendritic cells can migrate via the
blood to the spleen or via lymph into lymph nodes where
they are known as interdigitating cells. Close contact
between VADCs and macrophages suggest a possible
interaction between these cell types processing immuno-
logical information. VADCs may also migrate across ves-
sel walls (to eg, lymphoid tissue). Thus, they might serve
as common link between pathogenic events in the pe-
riphery as well as in neuroinvasion of prion diseases.28
We widen the spectrum of tissues which contain PrPSc.
Immunocompetent cells of vessel walls may participate in
PrPSc production (analogously to follicular dendritic cells)
and/or transport. As these cells might be in contact with
both neural and extraneural tissue, our results raise the
possibility of mobile cell-related spread of PrPSc and
infectivity. Early detection of abnormal PrP in lympho-
reticular tissues of gastrointestinal tract in mice after
intracerebral inoculation of the CJD agent supports this
theory.29 –31 In addition to established extraneural tis-
sue infectivity in vCJD,32 the occasional infectivity of
extraneural tissues of sCJD patients12 might result from
this kind of PrPSc transport. Furthermore, our results
suggest that PrPSc may be present in the blood, albeit
in sCJD probably at very low levels. Moreover, this
encourages the rationale for blood-based prion diag-
nostics using sensitive detection methods like protein
misfolding cyclic amplification.33
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